Pfizer Inc and BioNTech SE announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
- Read more about Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/pfizer-and-biontech-advance-covid-19-vaccine-strategy-with-study-start-of-next-generation-vaccine-candidate-based-on-enhanced-spike-protein-design
No comments:
Post a Comment